COMBINING
UNCOMMON EXPERTISE
WITH PROPRIETARY DATA
TO DRIVE UNIQUE INSIGHT
IPD Analytics identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market to offer:
-
Industry-leading drug life-cycle analysis
-
Clinical, formulary, procurement, and inventory-control insights for payers, providers, and suppliers
-
Brand and generic market impact forecasts
-
Pharmaceutical coding and reimbursement information
THE INDUSTRY LEADER
AN INDEPENDENT, THIRD-PARTY SOURCE
We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize...
With a unique team of experts, including:
Former Federal Circuit Patent Clerks and Litigators
Payor and Provider
Clinical Pharmacists
Brand and Generic Financial Forecasters from
Major Manufacturers
PhD Scientists with Pharmacy and Bioscience Backgrounds
Team of Researchers and Patent Searchers Utilizing Proprietary Data Aggregation Tools
We develop the
foundation that powers our solutions:
loss-of-exclusivity
timing
And provide meaningful, tailored insights for
specific use cases:
Key Litigation Updates & Analysis
Critical Headlines &
Day-by-day Trial Updates
Drug & Disease-Class Reviews
Formulary Planning Guidance
Loss-of-Exclusivity and
Market-Impact Forecasts
Analog Library with Accompanying Qualitative Analysis
Pipeline-Planning Tools
Coding & Reimbursement Insights
Drug-Price Tools
Scenario Analysis
We deliver these insights in multiple, easily consumable formats:
To serve stakeholders and institutional investors across the pharmaceutical industry:
Platform
Email Alerts
Direct Consultations
Podcast Episodes
Reports
Data Downloads
Manufacturers:
Brand Manufacturers
Generic Manufacturers
Specialty Drug Manufacturers
Active Ingredient Manufacturers
Institutional Investors:
Investment Managers
Hedge Funds
Mutual Funds
Sovereign Funds
Pension Funds
THE INDUSTRY LEADER
AN INDEPENDENT, THIRD-PARTY SOURCE
Since 2002, IPD Analytics has offered solutions that:
-
Deliver compelling insight and unique data assets to solve complex, multi-layered problems
-
Enable efficiency and transparency in an opaque pharmaceutical market
-
Offer a comprehensive look at the past to help predict future market shifts
We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize...
With a unique team of experts, including:
Former Federal Circuit Clerks, Patent Attorneys, and Litigators
Payer and Provider
Clinical Pharmacists
Brand and Generic Financial Forecasters from
Major Manufacturers
PhD Scientists with Pharmacy and Bioscience Backgrounds
Team of Researchers and Patent Searchers Utilizing Proprietary Data-Aggregation Tools
We develop the
foundation that powers our solutions:
loss-of-exclusivity
timing and innovative, product-launch tracking
And provide meaningful, tailored insights for
specific use cases:
Key Litigation Updates & Analysis
Critical Headlines &
Day-by-Day Trial Updates
Drug & Disease-Class Reviews
Formulary Planning Guidance
Loss-of-Exclusivity and
Market-Impact Forecasts
Analog Library with Accompanying Qualitative Analysis
Pipeline-Planning Tools
Coding & Reimbursement Insights
Drug-Price Tools
Scenario Analysis
Brand and Generic Launch Forecasts
Budget Impact Models
We deliver these insights in multiple, easily consumable formats:
To serve stakeholders and institutional investors across the pharmaceutical industry:
Online Platform
Email Alerts
Phone Consultations
Podcast Episodes
Reports
Data Downloads
Manufacturers:
Brand Manufacturers
Generic Manufacturers
Specialty-Drug Manufacturers
Active-Ingredient Suppliers
Payors, Providers, & Suppliers:
Payors
Health Systems
Wholesalers
Specialty & Retail Pharmacies
Long-Term Care Facilities
IDNs
GPOs
PBMs
Institutional Investors:
Investment Managers
Hedge Funds
Mutual Funds
Sovereign Funds
Pension Funds
Private Equity
OUR SOLUTIONS
IPD Analytics provides actionable insights to drive decisions.
We offer subscription-based access to our proprietary platforms, consultations, real-time email alerts, comprehensive reports, data downloads, podcast episodes, and more.
Pharmaceuticals | Biotech | Biosimilars
OTHER INDUSTRIES
OUR SUBSCRIBERS
IPD Analytics offers tech-enabled solutions to stakeholders across the pharmaceutical landscape.
PODCAST
IPD's Drug & Clinical Review:
The Premier Podcast for Drug Intelligence and Management Strategy
Within each episode, IPD's Executive Clinical Pharmacy Team discusses:
-
Drug pipeline intelligence and clinical strategy surrounding loss of exclusivity, high-cost and complex drugs, formulary planning, and pharmacy and therapeutics management
-
Impactful generic, brand, and biosimilar launches coming
down the pipeline
-
Strategies to improve outcomes, lower pharmacy spend, and optimize formulary design
-
Popular questions frequently asked by payers, providers, and manufacturers around the country
NEWSROOM
FEATURED
ARTICLE FEATURE
October 8, 2020
EY Announces Howard Krass founder and CEO of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Florida Award Winner
Ernst & Young LLP (EY US) today announced that Howard Krass of IPD Analytics, LLC was named an Entrepreneur Of The Year® 2020 Florida Award winner. The Entrepreneur Of The Year Awards program is one of the preeminent competitive awards for entrepreneurs and leaders of high-growth companies. Howard was recognized for his excellence in innovation, societal impact, commitment to building a values-based company, financial performance, and overall leadership. Howard Krass was selected by an independent judging panel. The award was announced through the program’s first-ever virtual awards gala, hosted by Deborah Norville, anchor of Inside Edition, on October 8, 2020. To watch the replay, visit the Florida program website.
SEE MORE
INSIGHT BRIEF
February 7, 2020
Authorized to Compete: Shifting Competitive Strategies Require a Fresh Look at Authorized Generics
Authorized generic (AG) drugs have existed for more than 40 years and have long been utilized as a life-cycle management strategy by manufacturers to compete with generics.
More recently, however, brand manufacturers are increasingly using AGs to compete with other brands as well. Shifts in contracting and rebate dynamics have made AGs a cornerstone of a “dual strategy” by which manufacturers attempt to capture and retain market share.
This new trend creates the need for complementary strategies on the part of payers and PBMs to preemptively manage AGs. Likewise, manufacturers should fully understand the factors impacting payer management of AGs in order to maximize their success.
DOWNLOAD NOW
PRESS RELEASE
May 9, 2019
